27771-25-1

Basic information

• Product Name: 1-Benzyl-4-hydroxypiperidine-4-carboxamide
• Synonyms: 1-Benzyl-4-hydroxypiperidine-4-carboxamide;1-Benzyl-4-hydroxy-piperidine-4-carboxylic acid amide
• CAS NO: 27771-25-1
• Molecular Formula: C₁₃H₁₈N₂O₂
• Molecular Weight: 234
• Mol File: 27771-25-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Benzyl-4-hydroxypiperidine-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-4-hydroxypiperidine-4-carboxamide(27771-25-1)
• EPA Substance Registry System: 1-Benzyl-4-hydroxypiperidine-4-carboxamide(27771-25-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 27771-25-1(Hazardous Substances Data)

Usage

General Description

"1-Benzyl-4-hydroxypiperidine-4-carboxamide" is a fine chemical compound which is a derivative of piperidine. Piperidines are a class of organic compounds that contain a nitrogen atom in a six-membered heterocyclic ring and exhibit a wide range of biological activities, making them significant in the field of pharmaceuticals. While specific information on "1-Benzyl-4-hydroxypiperidine-4-carboxamide" is limited, the compound could potentially be used for research and drug development purposes due to its structural features. However, safety, toxicity, and other key properties need to be thoroughly investigated before any potential applications can be determined.

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 71617-20-4 1-benzyl-4-hydroxy-4-piperidinecarbonitrile hydrochloride 
• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 

Downstream Products

• 25506-03-0 8-benzyl-2-(4-chloro-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27759-87-1 8-benzyl-2-(2-chloro-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 693285-66-4 4-hydroxypiperidine-4-carboxamide 
• 27760-00-5 2-m-tolyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27810-30-6 2-benzyl-2-methyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27810-29-3 2-(4-dimethylamino-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 23699-15-2 2-phenyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27810-36-2 8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-2-(4-methoxy-phenyl)-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27810-32-8 2-(2-chloro-phenyl)-8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27810-33-9 2-(4-chloro-phenyl)-8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27760-04-9 2-(3-chloro-phenyl)-8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27810-35-1 2-(3-fluoro-phenyl)-8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 27771-48-8 2-benzyl-8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-2-methyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 
• 25506-08-5 8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-2-m-tolyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one 

Relevant articles and documents

ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF

A compound of Formula (I) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 and Y are as defined herein.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists

Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.

3-SUBSTITUTED-6-ARYL PYRIDINES

3-substituted-6-aryl pyridines of Formula (I) are provided: Formula (I) wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.